Orakl Oncology raises $34m Series A for AI-powered 'virtual patient' cancer drug testing

What's the deal? Paris-based biotech Orakl Oncology has raised a $34m Series A to scale its AI-driven "virtual patient" platform, which models how cancer drugs will perform in patients before they reach clinical trials.

The round brings in Singular and Norrsken VCDealroom has a profile for this one. Try Dealroom →. Orakl Oncology previously raised an €11m seed round in December 2024 and a €3m round in October 2023.

The company, which grew out of research at École PolytechniqueDealroom has a profile for this one. Try Dealroom → and IP ParisDealroom has a profile for this one. Try Dealroom →, builds patient-derived tumour organoid models combined with AI to simulate drug efficacy — aiming to cut the cost and time of oncology drug development ahead of clinical trials.

Read more: Sifted

Image credit: History at NIH